LXGTF is in a $140-billion-dollar sector and is on the fast track to FDA approval. The device, if approved, since its for home use, has the potential to be sold at large retailers and online.
Take a look at a similar type of company, IRTC founded in 2005 which remotely measures and diagnoses cardiac arrhythmias- IRTC IPO was in October 2016 & began trading at around $25 per share and has more than doubled.
This looks like it is just the beginning for LXGTF.
News 
Market Data 
Discover 
